Raskob GE, Van Es N, Verhamme P, et al. A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study. ASH 59th Annual Meeting & Exhibition, abstract LBA-6.
Ublituximab plus ibrutinib versus ibrutinib alleen bij gerecidiveerde of refractaire hoogrisico CLL
mrt 2021 | Leukemie